文献速递先天性心脏病外科

儿童扩张型心肌病中的铁缺乏与贫血与严重疾病的临床、生化和血液学标志物及不良结局相关

Iron deficiency and anemia in pediatric dilated cardiomyopathy are associated with clinical, biochemical, and hematological markers of severe disease and adverse outcomes.
PubMed 文献 · J Heart Lung Transplant · 2023-11-25

该回顾性单中心研究纳入2010至2020年诊断为扩张型心肌病且有完整铁代谢检查的儿童,发现铁缺乏患病率高,且铁缺乏与更严重的临床表现(如使用正性肌力药、机械通气、贫血、NT-proBNP升高)及复合不良事件(机械循环支持、心脏移植或死亡)风险增加相关。作者认为在因心力衰竭就诊的扩张型心肌病患儿中应考虑铁替代治疗。

要点

  • 在有铁代谢检查的扩张型心肌病患儿中,铁缺乏患病率为62%。
  • 铁缺乏患儿更可能需要正性肌力药或通气支持,贫血发生率更高,NT-proBNP更高。
  • 铁缺乏与1年、2年和5年无复合不良事件生存率显著降低相关。

核心结论

  • 铁缺乏在扩张型心肌病患儿中高度流行,临床实践中铁代谢检查不足,但铁缺乏与严重心力衰竭及复合不良事件风险增加相关。
  • 作者认为因心力衰竭就诊的扩张型心肌病患儿应考虑铁替代治疗。

研究设计与样本

  • 回顾性单中心研究,纳入2010年至2020年诊断为扩张型心肌病且有完整铁代谢检查的儿童,共138例扩张型心肌病患者中47例有铁代谢检查结果。
  • 铁缺乏定义为以下四项中至少两项:铁蛋白<20 μg/L、铁<9 μmol/L、转铁蛋白>3 g/L或转铁蛋白饱和度<15%。
  • 比较铁缺乏与铁充足患儿之间的临床和实验室指标以及无复合不良事件(机械循环支持、心脏移植或死亡)生存率。

主要发现

  • 47例有铁代谢检查的患儿中29例(62%)存在铁缺乏。
  • 铁缺乏患儿接受正性肌力药的比例为59%(17例),高于铁充足患儿(p=0.005);接受有创或无创通气的比例为45%(13例),高于铁充足患儿(p=0.016)。
  • 铁缺乏患儿贫血发生率为76%(22例),高于铁充足患儿(p=0.004),NT-proBNP为1,590 pmol/L(IQR 456-3,447),高于铁充足患儿(p=0.001)。
  • 铁缺乏患儿1年无复合不良事件生存率为54%±10%,2年为45%±10%,5年为37%±11%,均低于铁充足患儿(p=0.011)。
  • 单因素Cox回归中,铁缺乏和贫血是复合不良事件的唯二显著预测因素。

关键数值与推荐

  • 铁缺乏定义:铁蛋白<20 μg/L、铁<9 μmol/L、转铁蛋白>3 g/L、转铁蛋白饱和度<15%中至少满足两项。
  • 铁缺乏患儿正性肌力药使用17例(59%),p=0.005;通气支持13例(45%),p=0.016;贫血22例(76%),p=0.004;NT-proBNP 1,590 pmol/L(IQR 456-3,447),p=0.001。
  • 铁缺乏患儿无复合不良事件生存率:1年54%±10%,2年45%±10%,5年37%±11%,与铁充足患儿比较p=0.011。

临床怎么用

  • 作者认为,因心力衰竭就诊的扩张型心肌病患儿应考虑铁替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited evidence regarding the prevalence and impact of iron deficiency (ID) in children with dilated cardiomyopathy (DCM). METHODS: Retrospective single-center review of all children between 2010 and 2020 with a diagnosis of DCM and complete iron studies. ID was defined as ≥2 of ferritin <20 μg/liter, iron <9 μmol/liter, transferrin >3 g/liter, or transferrin saturation (TSat) <15%. Clinical and laboratory indices and freedom from a composite adverse event (CAE) of mechanical circulatory support (MCS), heart transplant, or death were compared between children with and without ID. RESULTS: Of 138 patients with DCM, 47 had available iron studies. Twenty-nine (62%) were iron deficient. Children with ID were more likely to be receiving inotropes (17, 59%, p = 0.005) or invasive/noninvasive ventilation (13, 45%, p = 0.016) than those who were iron replete. They had a higher incidence of anemia (22, 76%, p = 0.004) and higher NT-proBNP (1,590 pmol/liter, IQR 456-3,447, p = 0.001). Children with ID had significantly less freedom from the CAE at 1-year (54% ± 10%), 2-years (45 ± 10), and 5-years (37% ± 11%) than those without (p = 0.011). ID and anemia were the only significant predictors of the CAE on univariate Cox regression. CONCLUSIONS: ID is highly prevalent in children with DCM. Iron studies are undermeasured in clinical practice, but ID is associated with severe heart failure (HF) and an increased risk of the CAE. The need for iron replacement therapy should be considered in children who present in HF with DCM.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Luxford JC, Casey CE, Roberts PA, et al. Iron deficiency and anemia in pediatric dilated cardiomyopathy are associated with clinical, biochemical, and hematological markers of severe disease and adverse outcomes. J Heart Lung Transplant. 2023. PMID: 38012978. doi:10.1016/j.healun.2023.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。